Last reviewed · How we verify
SDX-7320
At a glance
| Generic name | SDX-7320 |
|---|---|
| Sponsor | SynDevRx, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer (PHASE2)
- Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer (PHASE1, PHASE2)
- A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SDX-7320 CI brief — competitive landscape report
- SDX-7320 updates RSS · CI watch RSS
- SynDevRx, Inc. portfolio CI